News FDA experts back Novo Nordisk's key diabetes drug Novo hopes for blockbuster sales from semaglutide
News Automatic artificial pancreas shows promise in trial Experimental device requires no user input at all.
News J&J hopes FDA cardio label will limit Invokana damage Diabetes drug has been hit by amputation warning on label.
News No cardio protection indication for Novo's semaglutide - yet Danish pharma plans outcome trial to confirm benefits in SUSTAIN 6
News Novo aims for GLP-1 sales growth in China Novo expects Victoza and semaglutide to gain momentum.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.